Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE

Latini, David; Chan, June M.; Cowan, Janet E.; Arredondo, Shelley A.; Kane, Christopher J.; Penson, David F.; DuChane, Janeen; Carroll, Peter R.

doi:10.1016/j.urology.2006.08.1096

Cited by 19 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, another longitudinal study of men with prostate cancer treated with radiotherapy reported that diabetes predicted erectile dysfunction at 1 year of follow-up [5]. In the CaPSURE study [11], a longitudinal disease registry of men with prostate cancer, men with diabetes had poorer urinary control but not sexual or bowel function over a 24-month follow-up. In that study, men without diabetes actually reported a greater decline in sexual function than those with diabetes, although men with diabetes had worse function at baseline.…”

Section: Discussionmentioning

confidence: 99%

“…Few longitudinal and population‐based studies have evaluated the effect of comorbid conditions on general and cancer‐specific HRQL in men with prostate cancer. Previous studies have shown that prostate cancer survivors with moderate or severe cardiovascular disease (CVD) had a poorer HRQL compared with those without CVD over 4 years of follow‐up [9,10], and that having diabetes and a greater body mass index were more likely to result in significant declines in urinary function over time than having either diabetes or greater, BMI alone [11]. We used data from the longitudinal, population‐based Prostate Cancer Outcomes Study (PCOS) [12] to assess the relationship of prevalent and incident diabetes to general and cancer‐specific HRQL in men with non‐metastatic prostate cancer, followed up for 5 years from the time of diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study

et al. 2010

Self Cite

View full text Add to dashboard Cite

RESULTS• In total, we evaluated 1811 men, including 13% with prevalent (pre-prostate cancer diagnosis) diabetes, 12% with incident (postprostate cancer diagnosis) diabetes, and 75% who never reported being diagnosed with diabetes.• Generally, men with prevalent diabetes had the poorest scores on general HRQL and non-diabetic men the best scores, independent of treatment.• Similarly, men with prevalent diabetes had the lowest urinary control and sexual function scores over time, while men without diabetes had the highest scores. Men with incident diabetes reported intermediate scores. CONCLUSION• Prostate cancer survivors with comorbid diabetes have poorer general and cancerspecific HRQL than those without diabetes. KEYWORDS diabetes mellitus, health-related quality of life, prostate cancer, symptomsWhat's known on the subject? and What does the study add? Comorbid diabetes can affect prostate cancer treatment decision-making and outcomes. Few longitudinal studies have investigated the effect of comorbid diabetes on general and cancer-specific health-related quality of life (HRQL) in prostate cancer. Our study found that men with prevalent diabetes (pre-prostate cancer diagnosis) generally had the poorest general HRQL, urinary control and sexual function scores over time, independent of treatment. Non-diabetic men had the best scores and men with incident diabetes (postprostate cancer diagnosis) reported intermediate scores.Study Type -Therapy (outcomes research) Level of Evidence 2b OBJECTIVE• To investigate the association between prostate cancer, diabetes, and long-term general and cancer-specific health-related quality of life (HRQL) in a cohort of men with non-metastatic prostate cancer. PATIENTS AND METHODS• We used data from self-administered surveys to assess the HRQL of men with localized or locally advanced disease at 6 (baseline), 12, 24, and 60 months after initial diagnosis.• We examined changes in general and cancer-specific HRQL with repeated measures analyses using a mixed-model approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the CaPSURE study, a longitudinal disease registry of men with prostate cancer, men with DM who were treated with radical prostatectomy had worse urinary control over a follow-up period of two years [15]. Men with DM have been shown to have worse late GI and GU side effects after being treated with 3D conformal radiation therapy compared to nondiabetic men [16, 17].…”

Section: Commentmentioning

confidence: 99%

Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer

et al. 2012

View full text Add to dashboard Cite

Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525 patients treated in 1999 were reviewed to evaluate toxicity. Late GI and GU morbidities were graded according to the RTOG late morbidity criteria. Other factors examined were patient age, BMI, smoking history, and medical co-morbidities. Due to the low event rate for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results. Median follow-up time was 8.5 years. On CRR univariate analysis, only the presence of DM was significantly associated with GU toxicity grade >2 (P = 0.43, HR 2.35, 95% Cl = 1.03–5.39). On univariate analysis, RT and DM were significantly associated with late GI toxicity. On multivariable analysis, both variables remained significant (RT: P = 0.038, HR = 4.71, CI = 1.09–20.3; DM: P = 0.008, HR = 3.81, 95% Cl = 1.42–10.2). Conclusions. Late effects occur with all treatment modalities. The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP.

show abstract

“…The results of these latter studies indicate that the presence of DM in such patients compromises urinary functioning [13] and genitourinary complications [14] after treatment. However, these studies focused on the disease‐specific HRQoL of selected patients treated with either prostatectomy [13] or radiotherapy [14]. The effects of concurrent DM on generic and disease‐specific HRQoL in diabetic patients with prostate cancer treated with other therapies remain unclear.…”

Section: Introductionmentioning

confidence: 99%

“…urinary, sexual and bowel functioning and bother) as well as general HRQoL (e.g. physical, psychological, social and spiritual functioning) [5][6][7][8][9][10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Does diabetes mellitus as a comorbid condition affect the health‐related quality of life in prostate cancer survivors? Results of a population‐based observational study

et al. 2008

View full text Add to dashboard Cite

OBJECTIVE To assess the health‐related quality of life (HRQoL) of long‐term, disease‐free prostate cancer survivors and compare it with that of prostate cancer survivors with diabetes mellitus (DM), and a Dutch normative population, as comorbidity can have a major impact on HRQoL in cancer survivors. PATIENTS AND METHODS The Eindhoven Cancer Registry was used to select all men diagnosed with prostate cancer from 1994 to 1998. Questionnaires on HRQoL (Short Form 36) and prostate specific problems (University of California, Los Angeles Expanded Prostate Cancer Index) were sent to 964 patients, and 780 (81%) responded. Excluding patients with disease progression, the sample comprised 525 with prostate cancer and 65 with both prostate cancer and DM. Survivors with DM were more likely to have other comorbid conditions at the time of survey besides DM than were those without DM (74% vs 60%, P = 0.05). At 5–10 years after diagnosis, patients with DM reported worse General Health Perceptions than patients without DM or the normative population (means 52, 61 and 63; P < 0.001). Patients with DM also reported worse Vitality scores (59 vs 63; P < 0.001) than the normative population. Regression analysis indicated that DM was negatively associated with General Health Perceptions (β = −0.13; P < 0.01) and Vitality (β = −0.12; P < 0.01). Survivors with DM did not report worse urinary and bowel function or bother, nor more sexual problems than those without DM. CONCLUSIONS Except for general health perceptions and vitality, the HRQoL of prostate cancer survivors with or without DM was comparable to a normative population. Survivorship selection can possibly explain, in part, why patients with DM did not report worse generic or disease‐specific HRQoL than those without DM, as had been expected.

show abstract

Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE

Cited by 19 publications

References 18 publications

Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study

Diabetes mellitus and health‐related quality of life in prostate cancer: 5‐year results from the Prostate Cancer Outcomes Study

Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer

Does diabetes mellitus as a comorbid condition affect the health‐related quality of life in prostate cancer survivors? Results of a population‐based observational study

Contact Info

Product

Resources

About